Long non-coding RNAs: A crucial part of the vasculature puzzle.


Journal

Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615

Informations de publication

Date de publication:
03 2019
Historique:
received: 11 01 2018
revised: 19 02 2018
accepted: 21 02 2018
pubmed: 27 2 2018
medline: 29 5 2019
entrez: 27 2 2018
Statut: ppublish

Résumé

With the advent of empowering sequencing techniques over the past two decades, the scientific community has uncovered many underlying secrets of our genome. Non-coding transcripts covering a staggering 98% of our genome strongly suggest their involvement in diverse cellular pathways. A special class of non-coding RNAs (ncRNAs) namely long non-coding RNAs (lncRNAs) has garnered tremendous attention considering its implications in multiple developmental and pathophysiological processes. Accumulating evidence has established lncRNAs as robust regulators of pathways ranging from embryonic cell development to ultimate diseased phenotype. Here, in particular, we summarize the lncRNAs actively participating in the development of our vasculature and the ones which function as drivers or modulators of fatal vascular diseases.

Identifiants

pubmed: 29481972
pii: S1537-1891(18)30010-7
doi: 10.1016/j.vph.2018.02.008
pii:
doi:

Substances chimiques

RNA, Long Noncoding 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-138

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Ankita Garg (A)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.

Shashi Kumar Gupta (SK)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.

Thomas Thum (T)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany; REBIRTH Excellence Cluster, Hannover Medical School, Hannover, Germany; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: Thum.Thomas@mh-hannover.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH